Cargando…
Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an ‘old’ strategy
Acute respiratory distress syndrome (ARDS) related to SARS-CoV-2 infection has some unusual characteristics that differentiate it from the pathophysiology described in the more ‘typical’ ARDS. Among multiple hypotheses, a close similarity has been suggested between COVID-19 ARDS and neonatal respira...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441217/ https://www.ncbi.nlm.nih.gov/pubmed/34521648 http://dx.doi.org/10.1136/bmjresp-2020-000867 |
_version_ | 1783752830780178432 |
---|---|
author | Bhatt, Reena M Clark, Howard W Girardis, Massimo Busani, Stefano |
author_facet | Bhatt, Reena M Clark, Howard W Girardis, Massimo Busani, Stefano |
author_sort | Bhatt, Reena M |
collection | PubMed |
description | Acute respiratory distress syndrome (ARDS) related to SARS-CoV-2 infection has some unusual characteristics that differentiate it from the pathophysiology described in the more ‘typical’ ARDS. Among multiple hypotheses, a close similarity has been suggested between COVID-19 ARDS and neonatal respiratory distress syndrome (RDS). With this opinion paper, we investigated the pathophysiological similarities between infant respiratory diseases (RDS and direct neonatal ARDS (NARDS)) and COVID-19 in adults. We also analysed, for the first time, similarities in the response to exogenous surfactant administration in terms of improved static compliance in RDS and direct NARDS, and adult COVID-19 ARDS. In conclusion, we believe that if the pathological processes are similar both from the pathophysiological point of view and from the response in respiratory mechanics to a recruitment treatment such as surfactant, perhaps the latter could be considered a plausible option and lead to recruitment in clinical trials currently ongoing on patients with COVID-19. |
format | Online Article Text |
id | pubmed-8441217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-84412172021-09-16 Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an ‘old’ strategy Bhatt, Reena M Clark, Howard W Girardis, Massimo Busani, Stefano BMJ Open Respir Res Perspective Acute respiratory distress syndrome (ARDS) related to SARS-CoV-2 infection has some unusual characteristics that differentiate it from the pathophysiology described in the more ‘typical’ ARDS. Among multiple hypotheses, a close similarity has been suggested between COVID-19 ARDS and neonatal respiratory distress syndrome (RDS). With this opinion paper, we investigated the pathophysiological similarities between infant respiratory diseases (RDS and direct neonatal ARDS (NARDS)) and COVID-19 in adults. We also analysed, for the first time, similarities in the response to exogenous surfactant administration in terms of improved static compliance in RDS and direct NARDS, and adult COVID-19 ARDS. In conclusion, we believe that if the pathological processes are similar both from the pathophysiological point of view and from the response in respiratory mechanics to a recruitment treatment such as surfactant, perhaps the latter could be considered a plausible option and lead to recruitment in clinical trials currently ongoing on patients with COVID-19. BMJ Publishing Group 2021-09-14 /pmc/articles/PMC8441217/ /pubmed/34521648 http://dx.doi.org/10.1136/bmjresp-2020-000867 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Perspective Bhatt, Reena M Clark, Howard W Girardis, Massimo Busani, Stefano Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an ‘old’ strategy |
title | Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an ‘old’ strategy |
title_full | Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an ‘old’ strategy |
title_fullStr | Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an ‘old’ strategy |
title_full_unstemmed | Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an ‘old’ strategy |
title_short | Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an ‘old’ strategy |
title_sort | exogenous pulmonary surfactant in covid-19 ards. the similarities to neonatal rds suggest a new scenario for an ‘old’ strategy |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441217/ https://www.ncbi.nlm.nih.gov/pubmed/34521648 http://dx.doi.org/10.1136/bmjresp-2020-000867 |
work_keys_str_mv | AT bhattreenam exogenouspulmonarysurfactantincovid19ardsthesimilaritiestoneonatalrdssuggestanewscenarioforanoldstrategy AT clarkhowardw exogenouspulmonarysurfactantincovid19ardsthesimilaritiestoneonatalrdssuggestanewscenarioforanoldstrategy AT girardismassimo exogenouspulmonarysurfactantincovid19ardsthesimilaritiestoneonatalrdssuggestanewscenarioforanoldstrategy AT busanistefano exogenouspulmonarysurfactantincovid19ardsthesimilaritiestoneonatalrdssuggestanewscenarioforanoldstrategy |